Coeptis Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Mehalick
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 105 Bradford Road Wexford PA United States of America 15090
- IPO Date
- Dec 17, 2020
- CIK
- 0001759186
- Website
- coeptispharma.com
- Similar Companies
- Business
- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is a clinical-stage biopharmaceutical company that develops innovative cell therapy platforms for oncology, autoimmune diseases, and infectious diseases. The company offers an allogeneic immune effector cell generation platform utilizing FDA-regulated cord blood-derived CD34+ cells to produce natural killer (NK) cells and macrophages without HLA matching; DVX201, an unmodified allogeneic NK cell therapy in Phase 1 trials for relapsed/refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and acute viral respiratory diseases; CD38-GEAR-NK, autologous GEAR (Gene-Edited Antibody Resistant) NK cells in pre-clinical development for multiple myeloma and other CD38-related cancers; SNAP-CAR technology, a universal chimeric antigen receptor platform licensed from the University of Pittsburgh for allogeneic or autologous T and NK cells targeting hematologic malignancies, solid tumors, and autoimmune diseases via tunable tagged antibodies; and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute. Coeptis Therapeutics Holdings, Inc., founded in 2017, is headquartered in Wexford, Pennsylvania. In recent developments, the company licensed exclusive worldwide rights to the GEAR cell therapy platform from VyGen-Bio in 2021 and formed majority-owned subsidiary GEAR Therapeutics to advance GEAR-modified NK cells into first-in-human studies; expanded its SNAP-CAR license from the University of Pittsburgh to include autoimmune indications and NK cells; acquired the exclusive license for Deverra Therapeutics' allogeneic immunotherapy platform and DVX201 clinical assets in 2023, including onboarding Deverra's R&D site; completed the acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies division in December 2024 to integrate AI-powered marketing and robotic process automation tools for biotechnology and regulated industries; and anticipates close-out of DVX201 Phase 1 trials in 2024 with ongoing enrollment showing no dose-limiting toxicities.
Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market
Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application
Coeptis Receives Shareholder Approval Towards Z Squared Merger
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% – Time to Sell?
Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP
COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan
COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing